• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: November 12-17


ICYMI, this week we had articles about coverage from the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting, the availability of UCB's bimekizumab, FDA breakthrough therapy designation to QTORIN rapamycin for microcystic lymphatic malformations, and more.

Abby L. Allen, RN, NP: Update on Biologics for Atopic Dermatitis

What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.

Promising Results for Roflumilast Cream 0.15% From the INTEGUMENT Phase 3 Trials

A poster presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting found once daily roflumilast cream 0.15% safely and significantly improved atopic dermatitis.

Efficacy and Safety Data for Leukotriene Receptor Antagonists for Chronic Urticaria Presented at ACAAI

Late-breaking data adds important safety and efficacy data for leukotriene receptor antagonists augmentation in chronic urticaria treatment.

Award Recipient to Focus on Atopic Dermatitis in Native Americans

Kamran H. Imam, MD, hopes to unlock insights into the atopic disease burden among Native American populations.

Marcella R. Aquino, MD, FACAAI: Don’t Make a Rash Dx

Marcella R. Aquino details issues in differential diagnosis for rashes that mimic allergic skin conditions at the ACAAI Annual Meeting.

Exploring the Diagnostics of Urticaria at ACAAI

Session at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting explored issues in understanding and testing for physical urticaria.

Derm In The News: November 5-11

Keep up with the latest headlines in dermatology from the past week, including the rise of teledermatology platforms leading patients to opt out of in-person consultations, WHO and ILO estimates of non-melanoma skin cancer deaths attributable to outdoor work in the sun, and more.

Pointers With Portela: Understanding Health Insurance

In this week’s Pointers With Portela, the 208SkinDoc reviews medical health insurance on his podcast.

Reflecting on a Year of Meaningful Innovations

2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.

The Amazingly Wide, Ever-Expanding Reach of Dermatology

Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.

Tildrakizumab Significantly Improved Work Productivity and More in Patients With Plaque Psoriasis

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

UCB's Bimekizumab is Now Available

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

Nonablative Lasers Offer a Gentle Approach to Healthy Skin

In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.

Aging, Acne, and the Armamentarium: Hot Topics From the Science of Skincare Summit

Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.

No Significant Difference in BMI, Weight Regarding Switching Rates for Patients with Psoriasis

Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.

Dermatology Community Celebrates Nurse Practitioners This NP Week

Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).

The Journal Digest: November 15

This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.

Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions

Almirall, Absci Partner to Develop AI-Designed Therapies for Dermatologic Conditions

Revolutionizing Vitiligo Care: Dermatology Experts Offer Insights on Economic Factors

Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.

FDA Grants Breakthrough Therapy Designation to QTORIN Rapamycin for Microcystic Lymphatic Malformations

There are currently no FDA-approved therapies for the rare, genetic disease.

Frontline Forum Part 1: Topical Therapy for Corticosteroid-Responsive Dermatoses

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows

Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the US and is projected to maintain a substantial market lead over ritlecitinib.

Cancer Vaccine Plus Keytruda Improves Survival Without Relapse in Resected Melanoma

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

American Indian/Alaska Native Communities Face Barriers to Dermatologic Care, Disparities, and More

November is Native American Heritage Month. Access to dermatological health care has been a persistent challenge for individuals in the AIAN community.

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Hyperhidrosis is not rare. According to the International Hyperhidrosis Society, approximately 385 million people worldwide live with hyperhidrosis.

European Commission Approves Lebrikizumab for Atopic Dermatitis

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.

Purple Heart Project Seeks to Provide Veterans With Access to Dermatologic Care

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Dermatology's Purple Heart Project.

Shawn Kwatra, MD, Shares Highlights From the 12th World Congress on Itch

Kwatra presented on the unmet need for itch improvement in patients with skin of color.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.